<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045120</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-653</org_study_id>
    <nct_id>NCT03045120</nct_id>
  </id_info>
  <brief_title>Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States</brief_title>
  <official_title>Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, prospective study will characterize the impact of three approved
      first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and
      metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and
      initiating first-line TKIs in routine clinical practice in the US. All treatment decisions
      will be determined at the discretion of the treating physician(s) and data identifying the
      cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples
      (collected following 8 hours of fasting) will be collected during standard of care
      (SOC)/routine office visits. Additional research imaging will be performed and will be
      reviewed by core imaging laboratory. As the study is collecting data on management of CML,
      this study will not influence the prescribing or management practices at participating sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional, prospective study will characterize the impact of three approved
      first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and
      metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and
      initiating first-line TKIs in routine clinical practice in the US. All treatment decisions
      will be determined at the discretion of the treating physician(s) and data identifying the
      cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples
      (collected following 8 hours of fasting) will be collected during standard of care
      (SOC)/routine office visits. Additional research imaging will be performed and will be
      reviewed by core imaging laboratory. As the study is collecting data on management of CML,
      this study will not influence the prescribing or management practices at participating sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>changes in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in metabolic risk from baseline using metabolic lab values</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>echocardiography to assess left ventricular function</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary protein excretion to assess early vascular endothelial changes</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary calcium scoring to assess coronary artery narrowing</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic labs (Plasma Glucose, HbA1c, Fasting Lipids) for assessing the metabolic disease</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of first-line BCR-ABL TKIs in adults with CP-CML based on the number of treatment-related adverse events collected in the medical records</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes as described by the number of deaths from clinical assessments of disease status and mutational analysis</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes as described by the major molecular response from clinical assessments of disease status and mutational analysis</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes as described by the cytogenetic response from clinical assessments of disease status and mutational analysis</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to development of clinical outcomes from baseline to time of clinical outcome event based on clinical assessments</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of treatment patterns based on the number of changes in treatment dosing, interruptions, changes in therapy, duration of therapy and treatment discontinuations through the management of adverse events and comorbid disease</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of the demographic and clinical patient characteristics associated with initial treatment choice and changes of treatment based on the medical records</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum biomarkers that are predictive of an increased risk for cardiovascular or metabolic disease</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Phase Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>dasatinib cohort</arm_group_label>
    <description>Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imatinib cohort</arm_group_label>
    <description>Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nilotinib cohort</arm_group_label>
    <description>Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biomarker analyses will be collected for metabolic panels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly-diagnosed, treatment-naïve CP-CML patients who are ≥ 18 years at the time of CP-CML
        diagnosis who are scheduled to initiate treatment with dasatinib, imatinib, or nilotinib
        are eligible for enrollment. Enrolled patients (n=200) will be distributed across the 3
        patient treatment groups of newly diagnosed CP-CML patients who will initiate their first-
        line TKI treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years at the time of Ph+ CP-CML diagnosis

          2. Newly diagnosed chronic phase of Ph+ CP-CML, confirmed with cytogenetic and/or
             molecular testing at baseline

          3. Treatment-naïve and initiating treatment with dasatinib, imatinib, or nilotinib

          4. Willingness and ability to comply with routine office visits

        Exclusion Criteria:

          1. Any other prior or active non-CML active malignancy for which the patient is receiving
             treatment

          2. Participation in a therapeutic clinical trial for CML disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niraj Patel, 5308</last_name>
      <phone>872-222-7830</phone>
      <email>nirajpatel@prismsgrp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Cancer Institute</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Frezilis, 5301</last_name>
      <phone>630-269-2788</phone>
      <email>Karen.Frizelis@amitahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology &amp; Oncology Associates, LTD</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology of Northshore (North Shore Community Hospital)</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niraj Patel, 5336</last_name>
      <phone>872-222-7830</phone>
      <email>nirajpatel@prismsgrp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Springer, 5306</last_name>
      <phone>314-972-9600</phone>
      <email>bspringer@healthcareresearchnetwork.com</email>
    </contact>
    <contact_backup>
      <last_name>Rosemary Beyer</last_name>
      <phone>314-972-9600</phone>
      <email>rbeyer@healthcareresearchnetwork.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Sullivan, 5334</last_name>
      <phone>317-745-8000</phone>
      <phone_ext>1081</phone_ext>
      <email>Janet_Sullivan@ahni.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Davis, 5315</last_name>
      <phone>316-613-4318</phone>
      <email>Susan.Davis@cancercenterofkansas.com</email>
    </contact>
    <contact_backup>
      <last_name>LaDena Dosdall</last_name>
      <phone>316-613-4318</phone>
      <email>regulatory@cancercenterofkansas.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ARH Hazard</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracie McDaniel, 5324</last_name>
      <phone>606-487-7902</phone>
      <email>tmcdaniel@arh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Briana Barrow, 5323</last_name>
      <phone>318-212-8671</phone>
      <email>bbarrow@wkhs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Chandler, 5307</last_name>
      <phone>667-234-2966</phone>
      <email>echandle@ascension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Duyck, 5326</last_name>
      <phone>406-238-6288</phone>
      <email>heather.duyck@sclhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Witthoft, 5335</last_name>
      <phone>402-559-4828</phone>
      <email>mwitthof@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Krista Brown</last_name>
      <phone>402 559 4828</phone>
      <email>krista.brown@unmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Marfino, 5316</last_name>
      <phone>551-996-3416</phone>
      <email>kirsten.marfino@hackensackmeridian.org</email>
    </contact>
    <contact_backup>
      <last_name>Diana Baumgardt</last_name>
      <email>Diana.Baumgardt@hackensackmeridian.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambar Baez, 5327</last_name>
      <phone>718-920-2006</phone>
      <email>abaez@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Watkins, 5305</last_name>
      <phone>716-845-1516</phone>
      <email>Gretchen.Watkins@RoswellPark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Shelton, 5330</last_name>
      <phone>212-304-5485</phone>
      <email>rs3323@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony Greene, 5319</last_name>
      <phone>646-888-1001</phone>
      <email>greenea@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Gosciniak, 5311</last_name>
      <phone>646-962-9359</phone>
      <email>gag2663@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Munoz, 5312</last_name>
      <phone>631-638-2148</phone>
      <email>Sebastian.Munoz@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Hofecker</last_name>
      <phone>631-638-2148</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eubanks, 5329</last_name>
      <phone>252-744-1015</phone>
      <email>EUBANKSS@ecu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Douglas, 5314</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27111</phone_ext>
      <email>lisa.douglas@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Gasperin, 5302</last_name>
      <phone>503-418-9117</phone>
      <email>gasperin@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Spencer Thomas, 5333</last_name>
      <phone>801-213-4327</phone>
      <email>Spencer.Thomas@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lyon, 5309</last_name>
      <phone>425-297-5531</phone>
      <email>katie.lyon@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaysey Orlowski, 5303</last_name>
      <phone>206-667-1997</phone>
      <email>korlowsk@fredhutch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

